Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers

다국어 초록 (Multilingual Abstract)

Objective: Most BRCA1/2 carriers do not undergo risk-reducing salpingo-oophorectomy (RRSO) by the recommended age. This study aimed to find the incidence of precursor lesions and cancer after RRSO.
Methods: We retrospectively reviewed breast cancer patients identified as BRCA mutation carriers who underwent RRSO at Asan Medical Center, Seoul, Korea, from 2010 to 2014. From 2013, all cases were examined according to the Sectioning and Extensively Examining the Fimbria (SEE/FIM) protocol and underwent immunohistochemically staining. RRSO was performed in 63 patients, 27 in 2010 to 2012 and 36 in 2013 to 2014.
Results: The median age at RRSO was 46.5 years (range, 32 to 73 years). Occult invasive cancer was detected in eight patients, of ovarian origin in five and of tubal origin in three. All occult invasive cancer cases with metastasis were detected in patients older than 40 years. Of the 36 patients from the 2013 to 2014 cohort, seven showed p53 overexpression, one showed Ki-67 overexpression, two showed serous tubal intraepithelial carcinoma, and three showed occult cancer. The detection rate of precursor lesions or cancer was 36.1% (13/36). In the analysis according to age, precursor lesions were more common in BRCA1 mutation carriers younger than 40 years old (66.7% vs. 20.0%). In BRCA2 mutation carriers, precursor lesions were only detected in those older than 40 years of age, indicating the possible faster occurrence of precursor lesions in BRCA1 mutation carriers.
Conclusion: Many patients still tend to delay RRSO until after they are 40 years old. Our findings support the significance of RRSO before the age of 40 in germline BRCA mutation carriers.

참고문헌 (Reference)

1 Chai X, "Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers" 148 : 397-406, 2014

2 Medeiros F, "The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome" 30 : 230-236, 2006

3 Rocca WA, "Survival patterns after oophorectomy in premenopausal women: a population-based cohort study" 7 : 821-828, 2006

4 Hennessy BT, "Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer" 28 : 3570-3576, 2010

5 Powell CB, "Risk-reducing salpingooophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy" 23 : 127-132, 2005

6 Kauff ND, "Risk-reducing salpingooophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study" 26 : 1331-1337, 2008

7 Garcia C, "Risk management options elected by women after testing positive for a BRCA mutation" 132 : 428-433, 2014

8 Leblanc E, "Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development" 121 : 472-476, 2011

9 Finch A, "Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review" 70 : 261-265, 2011

10 Callahan MJ, "Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction" 25 : 3985-3990, 2007

11 Gross AL, "Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics" 2010 : 126295-, 2010

12 Sherman ME, "Pathologic findings at riskreducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199" 32 : 3275-3283, 2014

13 Parker WH, "Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study" 113 : 1027-1037, 2009

14 Cass I, "Occult cancers at risk-reducing salpingo-oophorectomies (RRSO) in BRCA mutation carriers" 125 (125): S86-, 2012

15 Michelsen TM, "Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study" 45 : 82-89, 2009

16 Marchetti C, "Hormone therapy in oophorectomized BRCA1/2 mutation carriers" 21 : 763-768, 2014

17 Michelsen TM, "Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer" 19 : 1029-1036, 2009

18 Greene MH, "Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?" 204 : 19-, 2011

19 Finch A, "Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers" 100 : 58-64, 2006

20 Shaw PA, "Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers" 22 : 1133-1138, 2009

21 Fakkert IE, "Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer" 51 : 400-408, 2015

22 McCarthy AM, "Bilateral oophorectomy, body mass index, and mortality in U.S. women aged 40 years and older" 5 : 847-854, 2012

23 Lim MC, "BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients" 135 : 1593-1599, 2009

24 George SH, "BRCA and early events in the development of serous ovarian cancer" 4 : 5-, 2014

25 Cass I, "A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers" 134 : 492-497, 2014